Brookline Capital Management started coverage on shares of Envoy Medical (NASDAQ:COCH – Free Report) in a report issued on Monday morning, Marketbeat reports. The firm issued a buy rating and a $9.00 target price on the stock. Brookline Capital Management also issued estimates for Envoy Medical’s Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.52) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.56) EPS.
Separately, Ascendiant Capital Markets lifted their price objective on shares of Envoy Medical from $8.50 to $8.75 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd.
Check Out Our Latest Research Report on Envoy Medical
Envoy Medical Stock Up 7.9 %
Envoy Medical (NASDAQ:COCH – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.08 million. Sell-side analysts forecast that Envoy Medical will post -1.22 earnings per share for the current fiscal year.
Institutional Trading of Envoy Medical
An institutional investor recently bought a new position in Envoy Medical stock. Virtu Financial LLC bought a new stake in Envoy Medical, Inc. (NASDAQ:COCH – Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 14,045 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Envoy Medical as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.59% of the company’s stock.
About Envoy Medical
Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.
Further Reading
- Five stocks we like better than Envoy Medical
- What is Forex and How Does it Work?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What Do S&P 500 Stocks Tell Investors About the Market?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Envoy Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envoy Medical and related companies with MarketBeat.com's FREE daily email newsletter.